SCHEMBL476398

SCHEMBL476398

CC(SCC(N)C(=O)O)C(N)C(=O)O

nearest known ligand 0.45

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
SLC7A5 Q01650 2/20 0.45
SLC1A3 P43003 3/20 0.41
SLC1A2 P43004 3/20 0.41
SLC1A1 P43005 2/20 0.41
KIF11 P52732 5/20 0.40
ARG1 P05089 1/20 0.40
ARG2 P78540 1/20 0.40
NOS2 P35228 3/20 0.40
NOS1 P29475 2/20 0.40
NOS3 P29474 1/20 0.40
BHMT Q93088 2/20 0.39
BHMT2 Q9H2M3 1/20 0.39
PTGS1 P23219 1/20 0.38
SLC7A11 Q9UPY5 1/20 0.38
GLO1 Q04760 1/20 0.38
ALDH1A1 P00352 1/20 0.37
ALOX15 P16050 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2032831 1.00 SLC7A5 (0.45) SLC7A5SLC1A3SLC1A2SLC1A1KIF11
SCHEMBL360210 1.00 SLC7A5 (0.45) SLC7A5SLC1A3SLC1A2SLC1A1KIF11
SCHEMBL360209 1.00 SLC7A5 (0.45) SLC7A5SLC1A3SLC1A2SLC1A1KIF11
SCHEMBL28948326 0.80 SLC7A5 (0.50) SLC7A5SLC1A3SLC1A2SLC1A1KIF11
SCHEMBL13988062 0.80 SLC7A5 (0.50) SLC7A5SLC1A3SLC1A2SLC1A1KIF11
SCHEMBL6542263 0.80 SLC7A5 (0.50) SLC7A5SLC1A3SLC1A2SLC1A1KIF11
SCHEMBL13902860 0.80 SLC7A5 (0.50) SLC7A5SLC1A3SLC1A2SLC1A1KIF11
SCHEMBL6542267 0.80 SLC7A5 (0.50) SLC7A5SLC1A3SLC1A2SLC1A1KIF11
SCHEMBL160076 0.80 SLC7A5 (0.42) SLC7A5SLC1A3SLC1A2SLC1A1KIF11
SCHEMBL5490023 0.80 SLC7A5 (0.42) SLC7A5SLC1A3SLC1A2SLC1A1KIF11

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 160 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2069473-A2 ANTIBIOTIC ANTIMICROBIAL AGENTS AND METHODS OF THEIR USE The Ohio State University Research Foundation (US) 2009-06-17 EP claimed
WO-2008091416-A2 ANTIBIOTIC ANTIMICROBIAL AGENTS AND METHODS OF THEIR USE THE OHIO STATE UNIVERSITY RESEARCH FOUNDATION (US) 2008-07-31 WO claimed
EP-1915389-A2 DIFFERENTIALLY PROTECTED ORTHOGONAL LANTHIONINE TECHNOLOGY Oragenics, Inc. (US) 2008-04-30 EP claimed
WO-2007022012-A2 DIFFERENTIALLY PROTECTED ORTHOGONAL LANTHIONINE TECHNOLOGY ORAGENICS, INC. (US) 2007-02-22 WO claimed
US-20260116929-A1 ANTI-GRAM-NEGATIVE BACTERIAL COMPOUND MURATA MANUFACTURING CO (JP) 2026-04-30 US disclosed
US-12428452-B2 Anti-gram-negative bacterial compound MURATA MANUFACTURING CO., LTD. (JP) 2025-09-30 US disclosed
CN-119932141-A Method for producing nisin by co-immobilized and co-fermented bacteria enzymes 河北工业大学 2025-05-06 CN disclosed
US-20250129328-A1 AN ISOLATED S. SALIVARIUS STRAIN AND ITS USE AS AN ANTIMICROBIAL PRODUCING PROBIOTIC MUNSTER TECHNOLOGICAL UNIVERSITY (IE) 2025-04-24 US disclosed
US-11987788-B2 Methods and compositions for changing the composition of the skin microbiome using complex mixtures of bacterial strains S-BIOMEDIC NV (BE) 2024-05-21 US disclosed
EP-3912630-B1 METHODS AND COMPOSITIONS FOR CHANGING THE COMPOSITION OF THE SKIN MICROBIOME USING COMPLEX MIXTURES OF BACTERIAL STRAINS S BIOMEDIC NV (BE) 2023-10-11 EP disclosed
WO-2023118232-A1 AN ISOLATED S. SALIVARIUS STRAIN AND ITS USE AS AN ANTIMICROBIAL PRODUCING PROBIOTIC MUNSTER TECHNOLOGICAL UNIVERSITY (IE) 2023-06-29 WO disclosed
EP-4198044-A1 AN ISOLATED S. SALIVARIUS STRAIN AND ITS USE AS AN ANTIMICROBIAL PRODUCING PROBIOTIC Munster Technological University (IE) 2023-06-21 EP disclosed
EP-0700998-A1 Recombinant mersacidin and a method for production HOECHST AKTIENGESELLSCHAFT (DE) 1996-03-13 EP disclosed
WO-1995030751-A1 LANTHIONINE-CONTAINING ANTIMICROBIAL COMPOUND CIBA-GEIGY AG (CH) 1995-11-16 WO disclosed
EP-0633939-A1 NISINS BIOTECHNOLOGY AND BIOLOGICAL SCIENCES RESEARCH COUNCIL (GB) 1995-01-18 EP disclosed
WO-1993020213-A1 NISINS AGRICULTURE AND FOOD RESEARCH COUNCIL (GB) 1993-10-14 WO disclosed
US-5231013-A Staphylococcus biosynthesis DR. KARL THOMAE GMBH (DE) 1993-07-27 US disclosed
EP-0508371-A1 Isolation and purification of lantibiotics Dr. Karl Thomae GmbH (DE) 1992-10-14 EP disclosed
EP-0342486-B1 ANTIBIOTIC Dr. Karl Thomae GmbH (DE) 1992-05-06 EP disclosed
EP-0342486-A1 Antibiotic Dr. Karl Thomae GmbH (DE) 1989-11-23 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12428452-B2 Anti-gram-negative bacterial compound NIT2, BPGM, FABP2 SLC7A5 234/4885SLC1A3 1345/4885SLC1A2 464/4885
US-20260116929-A1 ANTI-GRAM-NEGATIVE BACTERIAL COMPOUND TLL2, TMPO, BCL2L2 SLC7A5 838/4885SLC1A3 3034/4885SLC1A2 2122/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.